Safety of semaglutide
MM Smits, DH Van Raalte - Frontiers in endocrinology, 2021 - frontiersin.org
The glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide is the most recently
approved agent of this drug class, and the only GLP-1RA currently available as both …
approved agent of this drug class, and the only GLP-1RA currently available as both …
Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity
MM Jepsen, MB Christensen - Expert opinion on emerging drugs, 2021 - Taylor & Francis
Introduction: Obesity is a growing threat to public health, increasing risks of numerous
diseases and mortality, and impairing quality of life. If current trends continue, more than 1.1 …
diseases and mortality, and impairing quality of life. If current trends continue, more than 1.1 …
[HTML][HTML] The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission
Growing evidence indicates that the glucagon-like peptide-1 (GLP-1) system is involved in
the neurobiology of addictive behaviors, and GLP-1 analogues may be used for the …
the neurobiology of addictive behaviors, and GLP-1 analogues may be used for the …
Clinical recommendations to manage gastrointestinal adverse events in patients treated with Glp-1 receptor agonists: a multidisciplinary expert consensus
JJ Gorgojo-Martínez, P Mezquita-Raya… - Journal of Clinical …, 2022 - mdpi.com
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are indicated in type 2 diabetes and
obesity for their high efficacy in controlling glycaemia and inducing body weight loss …
obesity for their high efficacy in controlling glycaemia and inducing body weight loss …
Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and …
Aim We evaluated gastrointestinal (GI) adverse events (AEs) with once‐weekly semaglutide
2.4 mg in adults with overweight or obesity and their contribution to weight loss (WL) …
2.4 mg in adults with overweight or obesity and their contribution to weight loss (WL) …
Gastrointestinal adverse events associated with semaglutide: a pharmacovigilance study based on FDA adverse event reporting system
Y Shu, X He, P Wu, Y Liu, Y Ding, Q Zhang - Frontiers in public health, 2022 - frontiersin.org
Background Semaglutide was approved for treatment of type 2 diabetes mellitus (T2DM)
and chronic weight management in obesity or overweight adults. However, real-world data …
and chronic weight management in obesity or overweight adults. However, real-world data …
Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled …
X Gao, X Hua, X Wang, W Xu, Y Zhang… - Frontiers in …, 2022 - frontiersin.org
Objectives: This study aims to explore the weight loss effect and safety of semaglutide as a
conventional anti-obesity drug systematically in obese or overweight patients without …
conventional anti-obesity drug systematically in obese or overweight patients without …
Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta‐analysis including …
W Qin, J Yang, C Deng, Q Ruan… - Diabetes, Obesity and …, 2024 - Wiley Online Library
Aim To explore the safety and efficacy of subcutaneous semaglutide 2.4 mg, administered
once a week in non‐diabetic overweight or obese individuals. Methods A thorough search …
once a week in non‐diabetic overweight or obese individuals. Methods A thorough search …
The therapeutic potential of GLP‐1 receptor biased agonism
B Jones - British Journal of Pharmacology, 2022 - Wiley Online Library
Glucagon‐like peptide‐1 (GLP‐1) receptor agonists are effective treatments for type 2
diabetes as they stimulate insulin release and promote weight loss through appetite …
diabetes as they stimulate insulin release and promote weight loss through appetite …
Once-weekly semaglutide induces an early improvement in body composition in patients with type 2 diabetes: a 26-week prospective real-life study
Background: Body weight (BW) loss is an essential therapeutic goal in type 2 diabetes
(T2D). Glucagon-like peptide-1 receptor agonists are effective in reducing BW, but their …
(T2D). Glucagon-like peptide-1 receptor agonists are effective in reducing BW, but their …